What is the best medication for urinary incontinence?

Best Medication for Urinary Incontinence

For urgency urinary incontinence, when medication is needed after failed behavioral therapy, choose based on tolerability: darifenacin or tolterodine have the lowest discontinuation rates (similar to placebo), while solifenacin has the lowest overall risk for discontinuation due to adverse effects among all antimuscarinics. 1

Treatment Algorithm by Incontinence Type

Urgency Urinary Incontinence (Overactive Bladder)

First-line: Bladder training (non-pharmacologic) 1

When pharmacotherapy is needed:

• Preferred initial agents (based on tolerability):

  • Darifenacin or tolterodine - discontinuation rates equivalent to placebo 1
  • Solifenacin - lowest overall discontinuation risk among all antimuscarinics 1

• Alternative agents:

  • Beta-3 agonists (mirabegron) - should be tried before antimuscarinics in patients at risk for cognitive impairment 2
  • Fesoterodine - more effective than tolterodine but higher discontinuation rates (NNTH 58) 1

• Avoid: Oxybutynin has the highest discontinuation rate due to adverse effects (NNTH 14 vs tolterodine) 1

Stress Urinary Incontinence

Do NOT use systemic pharmacologic therapy - strong recommendation against it 1

The evidence shows no benefit for standard pharmacologic therapies used for urgency incontinence when applied to stress incontinence 1

Mixed Urinary Incontinence

Pelvic floor muscle training combined with bladder training is first-line 1. If pharmacotherapy needed, follow urgency incontinence algorithm above.

Key Prescribing Considerations

Dosing Strategy

• Tolterodine: Start with 2 mg twice daily, though 1 mg twice daily may be equally effective with less dry mouth 3
• Solifenacin: Start 5 mg once daily; can increase to 10 mg for better efficacy but expect increased dry mouth 3
• Fesoterodine: Start 4 mg once daily; 8 mg more effective but higher dry mouth risk 3

Formulation Preferences

Extended-release preparations of oxybutynin or tolterodine have significantly less dry mouth than immediate-release versions, with equivalent efficacy 1, 3

Critical Safety Warnings

Antimuscarinics and Dementia Risk: Meta-analysis shows association between antimuscarinic medications and increased risk of incident dementia and Alzheimer's disease, potentially cumulative and dose-dependent. Consider beta-3 agonists (mirabegron) before antimuscarinics, especially for chronic use 2

Absolute/Relative Contraindications for Antimuscarinics:

• Narrow-angle glaucoma
• Impaired gastric emptying
• History of urinary retention
• Use extreme caution in: diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson's disease, multiple sclerosis 2

Common Adverse Effects

• Antimuscarinics: Dry mouth (most common), constipation, blurred vision 1
• Beta-3 agonists (mirabegron): Nasopharyngitis, gastrointestinal disorders 1

Clinical Pitfalls to Avoid

1. Don't prescribe antimuscarinics for stress incontinence - they don't work 1

2. Don't start with oxybutynin - highest adverse effect profile and discontinuation rates 1

3. Screen for cognitive impairment before prescribing antimuscarinics - prefer beta-3 agonists in at-risk populations 2

4. Check post-void residual if combining therapies - antimuscarinic + alpha-blocker combinations increase residual volume 4

5. All medications require long-term compliance - counsel patients that effects require ongoing use 2

Evidence Quality Note

The guideline recommendations are based on high-quality evidence (Grade A) for pharmacologic treatment of urgency incontinence 1. The choice between equally efficacious agents should be driven by adverse effect profiles, not efficacy differences 1. Most antimuscarinics show similar efficacy; tolerability determines real-world success.